KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $107.8 million.

  • Novavax's Cash from Operations rose 17444.03% to $107.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$378.4 million, marking a year-over-year decrease of 31636.87%. This contributed to the annual value of -$87.3 million for FY2024, which is 8777.25% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Cash from Operations is $107.8 million, which was up 17444.03% from -$127.5 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Cash from Operations ranged from a high of $663.1 million in Q1 2021 and a low of -$342.4 million during Q4 2021
  • In the last 5 years, Novavax's Cash from Operations had a median value of -$127.5 million in 2025 and averaged -$57.9 million.
  • The largest annual percentage gain for Novavax's Cash from Operations in the last 5 years was 296925.57% (2021), contrasted with its biggest fall of 208782.52% (2021).
  • Quarter analysis of 5 years shows Novavax's Cash from Operations stood at -$342.4 million in 2021, then surged by 65.59% to -$117.8 million in 2022, then crashed by 50.05% to -$176.8 million in 2023, then rose by 2.03% to -$173.2 million in 2024, then skyrocketed by 162.24% to $107.8 million in 2025.
  • Its last three reported values are $107.8 million in Q3 2025, -$127.5 million for Q2 2025, and -$185.5 million during Q1 2025.